[Immunotherapy of pulmonary tuberculosis].
Khudzik. L B LB; Salina. T Iu TIu; Parolina. L E LE
Key Findings
- Thymogen plus interferon gave the fastest early improvement in TB patients
- Thymogen alone helped but was less effective than the combo
- The immune benefits grew after lung fibrosis healed, but patients still had significant residual lung changes
Practical Outcomes
- For most biohackers this research isn’t actionable—thymogen is being used as a TB treatment, not a general health enhancer. Unless you have active pulmonary TB, there’s no clear protocol to adopt for longevity or performance.
Summary
The study looked at people with severe lung TB and tested immune‑boosting drugs, including the peptide thymogen, alone or with interferon. They found that the combo gave the quickest improvement, but the benefits only grew after the lung scarring started to heal, and many patients still had lasting lung damage. This isn’t directly useful for healthy people trying to boost longevity or performance.
Abstract
The efficiency of treating patients with destructive tuberculosis by using different immune correctors was comparatively analyzed. Five hundred and fifty three patients were treated with thymalin, thymogen, human leukocytic interferon, and a combination of thymogen and interferon. The benefit from immunocorrector treatment was obtained early in the complex therapy and the best result was achieved by the use of thymogen plus interferon. However, the action of the two immunocorrectors increased when fibrous deformity of the lung was healed, followed by the development of pronounced residual changes.
Study Information
pubmed
1998